Insulet price target raised to $360 from $328 at Raymond James

Raymond James raised the firm’s price target on Insulet (PODD) to $360 from $328 and keeps an Outperform rating on the shares. The firm came away from spending time with Insulet’s management more confident in the growth profile, and sees various sources of potential upside to Street estimates, the analyst tells investors in a research note. Insulet is one of the strongest growth stories in Med Tech, which is supported by a differentiated offering in an underpenetrated market with favorable unit economics that drive significant free cash flow potential, the firm says.